Compare CLMB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | LCTX |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.8M | 366.2M |
| IPO Year | 1996 | 1996 |
| Metric | CLMB | LCTX |
|---|---|---|
| Price | $87.04 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $136.00 | $4.67 |
| AVG Volume (30 Days) | 54.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 14.29 | ★ 25.00 |
| EPS | ★ 4.64 | N/A |
| Revenue | ★ $652,517,000.00 | $9,499,000.00 |
| Revenue This Year | $2.60 | $6.32 |
| Revenue Next Year | $1.93 | $124.49 |
| P/E Ratio | $19.23 | ★ N/A |
| Revenue Growth | ★ 40.14 | 6.19 |
| 52 Week Low | $80.08 | $0.37 |
| 52 Week High | $145.00 | $2.09 |
| Indicator | CLMB | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 57.21 |
| Support Level | N/A | $1.55 |
| Resistance Level | $112.37 | $1.99 |
| Average True Range (ATR) | 6.98 | 0.10 |
| MACD | -3.34 | 0.02 |
| Stochastic Oscillator | 17.52 | 71.23 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.